Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge. This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified health care

provider. And now, on to the show. Welcome to episode 36 of Helix Talk. I'm your co-host Dr. King.

I'm Dr. Schumann. And I'm Dr. Patel. And before we get started with

today's episode, we wanted to have one brief amendment to our previous episode, episode 34,

that was actually emailed from one of our listeners. And the email was about that we mentioned

the conversion from Lantus to TOJA, which is one to one, but we overlooked the conversion from T2JO back to Lantus. So the Lantus to J.O., which is one to one, but we overlook the conversion from T2.J.O. back to Lantus.

So the Lantus to T2JO conversion is one to one, but if you're running into formulae issue

and you want to switch patient back to Lantus, you should do 80% of the T2JO dose to equalize

the Lantus dose.

And the typical scenario for this would be someone who's on Tujio as an outpatient but gets

admitted to the hospital.

And if the hospital only has Lantus, this is where that 20% reduction or 80% conversion

would play a role.

Absolutely.

So with that, we'll go ahead and jump into today's episode, which is

talking about some newer novel agents for schizophrenia. And Dr. Schumann, I'm sure that this is

right up your alley with kind of your expertise here. Yeah, we've been fortunate. Well,

over the last few years, we've had a number of medications for schizophrenia looking back to

Phanapt or Iloperidone or azone or latuda,

...